Brief: Halozyme Wins Injunction Stopping Manufacture And Sale Of Merck's Keytruda SC In Multiple European Markets
07/10/2026 13:45
BRIEF-Halozyme Wins Injunction Stopping Manufacture And Sale Of Merck's Keytruda SC In Multiple European Markets Oct 7 (Reuters) - Halozyme Therapeutics, Inc. HALO.O:
HALOZYME WINS INJUNCTION STOPPING MANUFACTURE AND SALE OF MERCK'S KEYTRUDA SC IN MULTIPLE EUROPEAN MARKETS
HALOZYME THERAPEUTICS - COURT ORDERS MSD BV TO STOP KEYTRUDA SC MANUFACTURE AND SALE IN EIGHT EUROPEAN COUNTRIES
HALOZYME THERAPEUTICS - INJUNCTION FORBIDS MSD FROM FACILITATING INFRINGEMENT BY AFFILIATES
HALOZYME THERAPEUTICS - COURT REJECTS MERCK'S ARGUMENTS THAT EP622 PATENT IS INVALID
HALOZYME THERAPEUTICS - IV VERSION OF KEYTRUDA REMAINS AVAILABLE AND NOT COVERED BY HALOZYME'S PATENT OR COURT INJUNCTION
Source text: ID:nPn3Y05TGa
Further company coverage: HALO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets